Evidence map›Paper›PMID 31510954›Full record

ArticleBMC nephrology2019

Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study.

Sehoon Park, Chung Hee Baek, Heounjeong Go, Young Hoon Kim, Sang-Il Min, Jongwon Ha, Yong Chul Kim, Jung Pyo Lee, Yon Su Kim, Kyung Chul Moon and 2 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Sehoon ParkDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Chung Hee BaekDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Heounjeong GoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Young Hoon KimDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sang-Il MinDepartment of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Jongwon HaDepartment of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Yong Chul KimKidney Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Jung Pyo LeeKidney Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Yon Su KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Kyung Chul MoonDepartment of Pathology, Seoul National University Hospital, Seoul, South Korea.
Su-Kil ParkDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hajeong LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. mdhjlee@gmail.com.ORCID 0000-0002-1873-1587
Ulsan College · KRSeoul National University Hospital · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough immunoglobulin A nephropathy (IgAN) is associated with an increased risk of renal allograft failure, evidences for its treatment, including renin-angiotensin-aldosterone system blockade (RAASB) usage, remain limited.

methodsIn this bi-center retrospective cohort study, we included patients who were recently diagnosed with IgAN through allograft biopsies. We identified their 6-month antihypertensive medication prescriptions and investigated the association between the medication types, albuminuria changes, and risk of 5-year death-censored-graft-failure (DCGF). The mixed effect model and cox regression analysis were used.

resultsA total of 464 allograft IgAN patients were included: 272, 38, 33, and 121 patients in the no antihypertensive medication, single agent RAASB, single agent beta blocker (BB)/calcium channel blocker (CCB), and combination therapy groups, respectively. High-degree albuminuria after 6 months of allograft IgAN diagnosis was an important prognostic parameter and a partial mediator for the association between the subgroups and 5-year DCGF. The usage of single RAASB was associated with decrement of albuminuria from allograft IgAN diagnosis (P for interaction = 0.03). The single BB/CCB group demonstrated significantly worse prognosis than the single RAASB group (adjusted hazard ratio, 2.76 [1.09-6.98]; P = 0.03).

conclusionsIn conclusion, RAASB may be beneficial for graft prognosis in early allograft IgAN patients who require single antihypertensive medication therapy, by means of reducing albuminuria. Further investigation of treatment strategy in allograft IgAN is warranted.

Indexed as

AdultAllograftsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersCohort StudiesFemaleGlomerulonephritis, IGAGraft RejectionGraft SurvivalHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsPrognosisRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersMineralocorticoid Receptor AntagonistsACE inhibitorsAllograftAngiotensin receptor blockadeIgA nephropathyProteinuriaRenin-angiotensin-aldosterone systemTransplantation

Identifiers

PMID31510954
PMCPMC6737644
OpenAlexW2972604592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.